Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Lineage Cell Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Lineage Cell Therapeutics, Inc.’s stock price such as:

• Lineage Cell Therapeutics, Inc.’s current stock price and volume
• Why Lineage Cell Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for LCTX from analysts
• LCTX’s stock price momentum as measured by its relative strength

About Lineage Cell Therapeutics, Inc. (LCTX)

Before we jump into Lineage Cell Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Want to learn more about Lineage Cell Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Lineage Cell Therapeutics, Inc..

Lineage Cell Therapeutics, Inc.’s Stock Price as of Market Close

As of September 04, 2026, 4:00 PM, CST, Lineage Cell Therapeutics, Inc.’s stock price was $1.080.

Lineage Cell Therapeutics, Inc. is down 1.82% from its previous closing price of $1.100.

During the last market session, Lineage Cell Therapeutics, Inc.’s stock traded between $1.080 and $1.100. Currently, there are approximately 249.50 million shares outstanding for Lineage Cell Therapeutics, Inc..

Lineage Cell Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Lineage Cell Therapeutics, Inc. Stock Price History

Lineage Cell Therapeutics, Inc.’s (LCTX) price is currently down 1.82% so far this month.

During the month of September, Lineage Cell Therapeutics, Inc.’s stock price has reached a high of $1.140 and a low of $1.080.

Over the last year, Lineage Cell Therapeutics, Inc. has hit prices as high as $2.090 and as low as $1.000. Year to date, Lineage Cell Therapeutics, Inc.’s stock is down 35.33%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Lineage Cell Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 04, 2026, there were 0 analysts who downgraded Lineage Cell Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Lineage Cell Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Lineage Cell Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Lineage Cell Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Lineage Cell Therapeutics, Inc. (LCTX) by visiting AAII Stock Evaluator.

Relative Price Strength of Lineage Cell Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 04, 2026, Lineage Cell Therapeutics, Inc. has a weighted four-quarter relative price strength of -5.68%, which translates to a Momentum Score of 33 and is considered to be Weak.

Want to learn more about how Lineage Cell Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Lineage Cell Therapeutics, Inc. Stock Price: Bottom Line

As of September 4, 2026, Lineage Cell Therapeutics, Inc.’s stock price is $1.080, which is down 1.82% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Lineage Cell Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.